Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation

Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, Stegger L, Schäfers M, Groth C, Kessler T, Lenz G, Stelljes M, Berdel WE

Abstract

Allogeneic stem cell transplantation (alloSCT) is still one of the most powerful tools for the treatment of hematological malignancies. The immune-mediated graft-versus-tumor (GVT) effect endows it with the potential to cure malignancies refractory to all other treatments. Nevertheless, it is associated with the risk of donor cell-mediated graft-versus-host disease (GVHD), which mainly contributes to its relevant morbidity and lethality. © 2016 Macmillan Publishers Limited. All Rights Reserved.